Liraglutide Injection Market By Type (Type I, Type II) By Application (Hypoglycemic, Weight Loss, Others) - Growth, Future Prospects & Competitive Analysis, 2016 - 2028

About this report

The global liraglutide injection market report explores the critical analysis of the liraglutide injection industry using key parameters. The report consists of investment strategies, the need for investments in the liraglutide injection industry, and the multiple benefits for investors. Importantly, this report sets out major changes in the global technical regulations for the liraglutide injection industry and how economic and non-economic barriers are helping the market grow. Moreover, the report analyses the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, and Tornado analysis. Key technological developments and other analyses include Porter's five forces analysis, PESTEL analysis, value chain analysis, etc.


Liraglutide Injection Market by Volume


Liraglutide Injection Market by Value


Liraglutide Injection Market, Tornado Analysis


Liraglutide Injection Market, STAR Analysis


Liraglutide Injection Market, SRC Analysis


Liraglutide Injection Market, Import-Export Data

Yes (On Demand)

Liraglutide Injection Market Pricing Analysis

Yes (On Demand)

Liraglutide Injection Market Segment Analysis

By Type (Type I and Type II)

By Application (Hypoglycemic, Weight Loss, and Others)

Liraglutide Injection Market, Regional Analysis

North America (the US and Canada)

Europe (Germany, UK, France, Italy, Spain, and the Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, South East Asia, and the Rest of Asia Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

Middle East and Africa (GCC Countries, South Africa, and the Rest of the Middle East and Africa)

Liraglutide Injection Market Key Companies

Novo Nordisk, Abbott Ltd, Reddy's Laboratories, Cipla, Senova Technology Co. Ltd, Shandong Octagon Chemicals Ltd, Apino Pharma Co. Ltd, Bachem Americas Inc, and Hybio Pharmaceutical

Liraglutide Injection Market Competitive Landscape

Market Share Analysis

Competitive Benchmarking

Key Players Market Positioning

Geographical Presence Analysis

Major Strategies Adopted


Key Highlights of the report

How are the major segments performing in the Liraglutide Injection Market?

  • In 2021, the type II segment led the global market and is expected to continue during the projection period. The use of liraglutide injection for type II diabetes is becoming more common around the world.
  • In 2021, the weight loss application segment held the largest global market share. Liraglutide injections are a popular weight-loss medication worldwide. It assists people in losing weight by reducing the amount of food they consume.

Which region dominated the liraglutide injection market?

North America dominated the global liraglutide injection market in 2021 and is expected to maintain its dominance throughout the forecast period. The rising geriatric population, soaring healthcare costs, geriatric population awareness, growing lifestyle-related diseases, and increasing costs of obesity and obesity-related diseases are all contributing factors to the region's high demand for liraglutide injections. The demand for better and more affordable anti-obesity medications is driving the growth of the North American liraglutide injection market during the forecast period due to modern R&D facilities and novel therapeutic developments by major regional players.

How is US Market Performing in the Liraglutide Injection Market?

The market for liraglutide injection in the United States is expected to expand significantly during the forecast period owing to the rising prevalence of obesity and diabetes. Novo Nordisk manufactures the diabetes medication liraglutide injection. Liraglutide injection is also widely used in the country to treat hypoglycemia. It helps to keep blood sugar levels within normal ranges by increasing pancreatic insulin release and decreasing liver sugar production. Besides, as people become more aware of the dangers of obesity, there is a surge in concern about being overweight, leading to a shift in consumer preference for anti-obesity drugs like liraglutide injection, which is expected to show positive market growth during the forecast period. Novo Nordisk recently launched Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition in the United States.

What is the competitive environment of the liraglutide injection market?

The liraglutide injection market is highly consolidated, with major manufacturers holding a global presence, including Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. Liraglutide formulation belongs to the GLP-1 agonist class of drugs. The GLP-1s are currently unavailable in generic form as they are a patent-protected product. Human glucagon-like peptide-1 is an analog found in liraglutide (GLP-1). It is classified as a GLP-1 receptor agonist and is 97% homologous to the native GLP-1 by modifying arginine for lysine at position 34. It received FDA approval for type 2 diabetes management in January 2010 and is now the sole property of Novo Nordisk A/S. Liraglutide is marketed as Victoza in the United States, United Kingdom, India, UAE, Japan, Kuwait, Canada, Europe, Iran, and the Philippines. Saxenda is the brand name under which liraglutide is marketed in Switzerland, Indonesia, Australia, Iran, Canada, Israel, Brazil, the United Kingdom, and the United States. Saxenda and Victoza contain the same active ingredient, liraglutide, and should not be combined or used with other GLP-1 receptor agonist medications.

Executive Summary

How does the rising prevalence of diabetes play an important role in the liraglutide injection market?

Approximately 463 million adults populations are expected to have type 2 diabetes in 2019, according to the International Diabetes Federation (IDF). A combination of genetic and lifestyle disorders contributes to the progression of the disease. Three clinical factors, including increased insulin resistance, elevated hepatic glucose production, and decreased insulin secretion, are considered to contribute to the pathophysiology of type 2 diabetes. The rising incidence of diabetes, growing public awareness of diabetes and its complications, and the expanding need for innovative therapies for treating diabetes are the main factors propelling the growth of the global liraglutide injection sales market. Liraglutide injection helps with blood glucose control.

Liraglutide has been shown to lower the risk for nonfatal myocardial infarction, nonfatal stroke, and the first occurrence of cardiac mortality in subjects with elevated cardiovascular risk. Young adults worldwide are increasingly using tobacco, drinking alcohol, eating fast food, and leading sedentary lifestyles, which will further cause the obesity market to grow significantly in the upcoming years. According to the World Health Organization (WHO), obesity is expected to affect 13% of people worldwide. Additional clinical studies have demonstrated that the prevalence rates for men and women are 11% and 15%, respectively. The FDA recently approved liraglutide injection for adults with type II diabetes mellitus, either in combination with other diabetes medications or as standard treatment when dieting. Adults with chronic weight problems may also use liraglutide with a healthy diet and regular exercise. Liraglutide injections resulted in greater weight loss than other glucagon-like peptide analogs.


Which are the key investments by the liraglutide injection market players?

The existence of high unmet medical needs for obesity management therapeutic interventions, combined with increased R&D investments, is the primary factor driving the growth of the liraglutide injection industry. The major players in the liraglutide injection market heavily invest in new product approvals, acquisitions, collaborations, and partnerships to broaden their global market reach. For instance, Novo Nordisk A/S recently acquired six companies, four of which were acquired within the last five years. Novo Nordisk's largest acquisition was Dicerna Pharmaceuticals in 2021 for USD 3.3 billion. Novo Nordisk A/S has made acquisitions in two nations and two different US states. Life science is the industry the company targets the most (100%).

Some major players in the liraglutide injection market are Novo Nordisk, Abbott Ltd, Reddy's Laboratories, Cipla, Senova Technology Co. Ltd, Shandong Octagon Chemicals Ltd, Apino Pharma Co. Ltd, Bachem Americas Inc, and Hybio Pharmaceutical.

What are the Major Driving Factors for the Liraglutide Injection Market?

The growing prevalence of Type II diabetes around the world drives market expansion. Environmental and lifestyle changes brought about by industrialization and migration to urban areas from rural areas may significantly impact the global Type II diabetes pandemic. Type II diabetes is a devastating condition characterized by hyperglycemia caused by insulin resistance, impaired insulin secretion, or both. Increased demand for liraglutide injectable medicine to treat type II diabetes will drive global market growth in the coming years. Besides, gestational diabetes in women raises the risk of developing type II diabetes later in life. The rising prevalence of gestational diabetes among women is expected to propel the global liraglutide injection market growth during the forecast period.

What are the Major Risks for the Liraglutide Injection Market?

The serious side effects of liraglutide are expected to hamper global market growth. Gastroenteritis, low blood sugar, kidney diseases (kidney failure), severe allergic reactions, gallbladder issues, and kidney stones are typical side effects. Other potential side effects involve thyroid tumors, cancer, an increase in heart rate, and severe allergic reactions. The high cost of this liraglutide injection may also limit its market growth over the forecast period.

Which is the key application in the liraglutide injection market?

The weight loss segment is anticipated to grow the fastest during the forecast period. Liraglutide injections are a well-known weight-loss therapy all over the world. It helps individuals lose weight by limiting the amount of food they eat. Liraglutide injection may also promote increased calorie burn. This injection is commonly used to treat obesity and obesity-related conditions. Liraglutide injection also postpones the time the stomach is empty, slowing food digestion and absorption and lowering blood sugar levels after meals. Liraglutide Injection also suppresses appetite, which can aid in weight loss. It works by lowering your food intake and assisting your body in burning more fat. Injections of liraglutide can help type II diabetics further control their blood sugar levels.

How is the liraglutide injection market performing in regions?

The North American liraglutide injection market is expected to expand significantly during the forecast period. The rapidly increasing prevalence of type 2 diabetes is primarily driving the region's liraglutide market growth. According to the American Diabetes Association (ADA), type 2 diabetes affects nearly 9% of the population in the United States. The USFDA's supportive regulatory framework for the marketing and selling liraglutide injection also contributes to the expansion of the regional market.

Europe is the second-largest regional market for liraglutide injections. The growing prevalence of obesity in the region's young population drives the region's liraglutide injection product demand. The developed healthcare infrastructure and widespread public awareness of the efficacy of the treatment of liraglutide in controlling the prevalence of type II diabetes and obesity in the region are expected to make Europe the region with the fastest-growing region, mainly in the liraglutide market.

What is the regulatory landscape for the liraglutide injection market?

The FDA has approved the liraglutide injection as an adjunct treatment to diet and exercise for improving glycaemic control in adults with type II diabetes. The regulatory approval allows liraglutide injection to be used as a monotherapy, as a second-line treatment, and in combination with other oral diabetes medications and is credited with driving the market. Moreover, the efforts of liraglutide injection manufacturers to obtain regulatory approvals for new liraglutide products are expected to drive market growth throughout the forecast period. For instance, Novo Nordisk reported in December 2020 that the US FDA had approved a revised label for Saxenda (Liraglutide) injection of 3 mg for use in the treatment of obesity in adolescents (12-17 years) with body weight over 60 kg and an initial body mass index (BMI) equivalent to 30 kg/m2 or higher for adults, as a supplement to lower-calorie meals and increased physical activity.

What is the Market Size of the Liraglutide Injection value?

The global liraglutide injection market is anticipated to grow at a substantial CAGR of 9.3% in the upcoming years. The global liraglutide injection industry is estimated to be worth USD 4.4 billion in 2021 and is expected to be worth USD 7.5 billion by 2028.

What are the major players planning for the future of the liraglutide injection market?

Key players are involved in the regulatory approval of new product formulations and the launch of newly developed products. Increased funding for liraglutide R&D initiatives is also expected to aid the future growth of the global liraglutide injection sales market. Moreover, growing awareness of various weight-control drugs for treating obesity, combined with technological advancement, further drives the global market growth. The formulations of drugs that act as Glucagon-like peptide-1 receptor agonists have undergone several modifications owing to increased technological development. Players are attempting to introduce new uses for liraglutide injection, including the management of obesity. For instance, AstraZeneca's once-weekly injectable suspension, Bydureon BCise (Liraglutide extended-release), was regulatory approved in July 2021 for the treatment of type 2 diabetes (T2D) to enhance glycaemic control in pediatric patients (10 to 17 years).

Segmentation of Global Liraglutide Injection Market -

Global Liraglutide Injection Market – By Type

  • Type I
  • Type II

Global Liraglutide Injection Market – By Application

  • Hypoglycemic
  • Weight Loss
  • Others

Global Liraglutide Injection Market – By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Frequently asked questions about the global liraglutide injection market

The COVID-19 pandemic positively impacted the global liraglutide injection market. In patients with COVID-19, diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes, including a higher risk of terminal illness or death. Liraglutide, like glucagon, is a peptide1 (GLP1) receptor, an agonist. As a result, GLP-1RAs have been identified as potential candidates for treating COVID-19 infection patients with or without type 2 diabetes, and they are excellent antidiabetic (glucose-low

North America accounted for the most heightened share in the global liraglutide injection market.

The rising prevalence of type II diabetes, the growing geriatric population, and the increasing preference for weight-loss therapies are driving the growth of the global liraglutide injection market.

The type II segment had a major share in the global market in 2021.

The weight loss segment had a major share in the global market.

Liraglutide Injection Market Scope

Report Attribute Details
Market Value in 2021 USD 7.5 billion
Market Value in 2028 USD 4.4 billion
CAGR 9.3%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Published Date:  Nov 2022
Category:  Medical Devices
Report ID:   60819
Report Format:   PDF
Pages:   120
Rating:    4.5 (50)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support